Sunil Arora, MD
Internal Medicine · San Bernardino, CANPI 1962583104
Payments from drug & device makers
Across 76 payments — averaging $107.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$3K
- Actelion Pharmaceuticals US, Inc.$3K
- Cook Incorporated$370
- AstraZeneca$305
- GSK$264
- Merck$195
- plus $897 from 19 others
What the payments were for
- Consulting fees$2,30028%
- Speaking & faculty fees$2,69533%
- Travel & lodging$6308%
- Food & beverage$2,18227%
- Education$3725%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 7 | $3,159 |
| Actelion Pharmaceuticals US, Inc. | 18 | $2,989 |
| Cook Incorporated | 1 | $370 |
| AstraZeneca | 7 | $305 |
| GSK | 9 | $264 |
| Merck | 5 | $195 |
| Boehringer Ingelheim | 7 | $185 |
| United Therapeutics Corporation | 1 | $148 |
| Inari Medical, Inc. | 1 | $139 |
| Philips North America LLC | 2 | $62 |
| Sanofi | 1 | $61 |
| Amgen(2 entities) | 2 | $54 |
| Resmed Corp | 2 | $35 |
| Advanced Respiratory, Inc | 1 | $35 |
| Pfizer | 2 | $27 |
| CSL Behring | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$3,018
- OPSUMIT$2,440
- UPTRAVI$2,440
- Blue Rhino$370
- TYVASO$148
- FLOWTRIEVER CATHETER, S$139
- CT THROMBECTOMY SYSTEM KIT$139
- BREZTRI$125
- AREXVY$122
- WINREVAIR$122
- Kerendia$108
How this compares
$8,179 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 92 | $1,227,652 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 899 | $578,305 |
| OzempicSemaglutide | 293 | $276,551 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 51 | $144,488 |
| XolairOmalizumab | 36 | $133,216 |
| JardianceEmpagliflozin | 116 | $112,687 |
| EliquisApixaban | 117 | $107,970 |
| EntrestoSacubitril/Valsartan | 99 | $72,426 |
| JanuviaSitagliptin Phosphate | 71 | $67,011 |
| NucalaMepolizumab | 18 | $64,233 |
| Dupixent SyringeDupilumab | 17 | $61,186 |
| Serevent DiskusSalmeterol Xinafoate | 142 | $60,063 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 1,172 | $40,874 |
| Spiriva RespimatTiotropium Bromide | 69 | $39,846 |
| Fluticasone Propionate HfaFluticasone Propionate | 140 | $32,542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Jardiance, Spiriva Respimat, Stiolto Respimat | $185 | $1,387,131292 claims |
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $264 | $679,6201,024 claims |
| PfizerEliquis | $27 | $107,970117 claims |
| MerckJanuvia, Steglatro | $195 | $78,289104 claims |
| AmgenProlia | $54 | $29,18518 claims |
| AstraZenecaFarxiga, Symbicort | $305 | $20,89863 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $17 | $17,72575 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Bernardino
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.